


# AUTHOR INDEX

## VOLUME 19, 1999

- Amato, Anthony A., 45
- Barcellos, Lisa F., 281
- Barohn, Richard J., 45
- Berger, Joseph R., 101, 193
- Bird, Thomas D., 253
- Bouchard, Jean-Pierre, 59
- Brais, Bernard, 59
- Breakefield, Xandra O., 271
- Brewer, George J., 261
- Chamberlain, Jeffrey S., 323
- Chance, Phillip F., 353
- Ciacchi, Joseph D., 213
- Clifford, David B., 185
- Cohen, Bruce A., 201
- Cole, N., 407
- Di Rocco, Alessandro, 151
- Fardeau, M., 59
- Fink, John K., 249, 261, 301, 339
- Hartigan-O'Connor, Dennis, 323
- Hauser, Stephen L., 281
- Hayden, Michael R., 385
- Hedera, Peter, 261, 301
- Hopkins, Linton C., 67
- Keller, Marcel P., 353
- Kissel, John T., 1, 5, 35
- Klein, Christine, 271
- Lanska, Douglas J., 105
- Leavitt, Blair R., 385
- Leppert, Mark F., 397
- Levy, Robert M., 213
- Lindblad, Kerstin, 289
- Major, Eugene O., 193
- Marra, Christina M., 177
- McArthur, Justin C., 129
- McDaniel, D.O., 419
- Mendell, Jerry R., 1, 5, 9
- Mintz, Mark, 165
- Nath, Avi, 113
- Oksenberg, Jorge R., 281
- Ozelius, Laurie J., 271
- Pandolfo, Massimo, 311
- Pascuzzi, Robert M., 3, 87, 103, 235, 247
- Ptáček, Louis J., 363
- Rouleau, Guy A., 59
- Sacktor, Ned, 129
- Schalling, Martin, 289
- Selnes, Ola, 129
- Shoffner, John M., 341
- Siddique, T., 407
- Simpson, David M., 157
- Singh, Nanda, 397
- St. George-Hyslop, P.H., 371
- Subramony, S.H., 419
- Tawil, Rabi, 81
- Tellez, Claudia, 213
- Thornton, Charles, 25
- Tomé, Fernando M.S., 59
- Tsao, Chang-Yong, 9
- Vig, P.J.S., 419
- VonRoenn, Jamie, 213
- Wagener, Maylene E., 67
- Warren, Stephen T., 67
- Weber, Thomas, 223
- Wellington, Cheryl L., 385
- Wulff, Enrique A., 157
- Zacharias, Alan S., 67



# SUBJECT INDEX

## VOLUME 19, 1999

- Acquired immunodeficiency syndrome, 105–110, 113, 129–132, 151–154, 157–161, 165–166, 201–209, 213–219, 223–229
- Adenoviral vector technology, 326–327
- Adenoviral vectors, transfer to both proliferating and nonproliferating cells using, 84–85
- Adjunctive therapies for HIV dementia, 146
- Adolescent-onset PTD of mixed type, dystonia 6, 274
- Adult-onset focal dystonia, dystonia 7, 275
- AIDS, *see* acquired immunodeficiency syndrome
- AIDS, incidence, survival and mortality of, 107–108
- AIDS-related lymphomas, immunosuppression and the molecular biology of, 213–214
- Algorithm for patient diagnosis with OXPHOS defects, 343–345
- Alzheimer disease, the mitochondrial genome and, 379
- Amyloid precursor protein, 372–373
- Amyotrophic lateral sclerosis, pathology and diagnosis of, genetics of, mechanism of the disease, 411–412
- Anabolic steroids, 83
- Anticopper drug treatment for Wilson's disease, 265–267
- Anticopper drugs, various phases and classes of patients in the application of, 266–267
- Antiretroviral therapy, effect on HIV levels, CNS penetration, 142–144
- Apolipoprotein E gene, analysis revealed that the gene likely responsible for the genetic locus on chromosome 19 was the, 373–374
- Arachidonic acid, metabolites, the synthesis of, 121
- Arrhythmia, 69, 73
- Asymptomatic at-risk patients, the other major scenario in DNA testing is the genetic evaluation of, 256
- Autonomic neuropathy, 162
- Autosomal dominant HSP, 303, 305
- Autosomal dominant nocturnal frontal lobe epilepsy, 399–400
- Autosomal recessive HSP, 302–303, 305
- Autosomal recessive PTD, 275
- Bacillary angiomatosis, neurologic complications associated with, 180
- Becker dystrophy, 5, 12–13, 89
- Benign familial neonatal convulsions, 398–399
- Biochemistry and genetics of oxidative phosphorylation, 342–343, 345
- Blood-brain barrier, mechanism of viral entry across the, 115
- Bone marrow cell transplantation, 85
- Brain, release of viral particles infecting cells, 115
- Candidate genes, in relation to HSP genes, 304
- Carriers of EDMD, 73
- Caspase inhibition, therapeutic approach for HD, 394
- Cellular targets of HIV infection, 139–140
- Central nervous system, the effect of Friedreich's ataxia on the, 312
- Central nervous system, viral strains in the, entry of HIV into the, 116, 140
- Cerebellar ataxia, Leigh disease and, 346–347
- Cerebrospinal fluid analysis for the diagnosis of HIV-related neurologic diseases, 223–229
- Cerebrospinal fluid, laboratory examinations and investigations of HIV-1 infection in, 171–172
- Charcot-Marie-Tooth neuropathy, 354
- Chemokine dysregulation in HIV encephalopathy, 116–117
- Children, HIV-associated neurologic disease in, 165–174
- Children, the DNA testing of, the role of testing in the adoption of, 257–258
- Chromosome 12 locus, 378
- Chromosome 2p-linked HSP, trinucleotide repeat expansion in, 303–304
- Chromosome 4q35, 41
- Clinical and genetic evaluation of CMT, 358
- Clinical features and host factors associated with PML, 195–196
- Clinical presentation of PCNSL, 215
- CMT, *see* Charcot-Marie-Tooth neuropathy, 354
- CMT type 1A, 354
- CMT type 1B, 354–355
- CMV, *see* cytomegalovirus
- CMV encephalitis, 186
- CMV neurologic disease, diagnosis of, therapy for, 187–188
- CMV radiculomyelitis, it is not rare for encephalitis to be associated with the presentation of, 186
- CNS, *see* central nervous system
- CNS lymphoma, 213–214
- CNS toxoplasmosis, 204–206
- Combination art, effects of the treatment on HIV dementia, 145
- Congenital muscular dystrophies, 17–20
- Contracture, 68, 73–75
- Corticosteroids, 82–83
- Costs of DNA-based tests, in relation to other diagnostic tests, 255
- Creatine kinase, 11, 17–19, 27, 39
- Cryptococcal meningitis, background, clinical manifestations of, diagnosis of, treatment of, 181–182
- CTG repeats, 25–28, 30–31
- Cytokine dysfunction in HIV encephalopathy, 116
- Cytomegalovirus, the most common cause of viral neurologic complications encountered in HIV infection is, 185
- Dejerine-Sottas syndrome, 355
- Demyelinating neuropathies, other forms of, 357
- Depression, a serious risk for persons who have tested positive for a neurogenetic disease is, 256–257
- Depression, in children and adolescents with HIV-1 infection, 169
- Diabetes mellitus, about 10% of Friedreich's ataxia patients develop, 313–314
- Diagnosis and prognosis of DNA testing, 254–255
- Diagnosis and treatment of Wilson's disease, 261–268
- Diffuse infiltrative lymphocytosis syndrome, clinical presentations of, 162
- Distal myopathies, historical perspective, 45–46
- Distal symmetric polyneuropathy, clinical and pathologic features as a neurologic complication of AIDS, 158–161
- Distal, 45–46, 49–51, 53–55
- DMD, *see* Duchenne muscular dystrophy
- DMD and dystrophin, salient features of, 324–325
- DNA diagnosis, identification of the CAG expansion mutations and, 422–423
- DNA testing, symptomatic patients and, treatment of, 254, 256

- Dominant ataxias, clinical diagnosis of, 420-421  
 Dominantly inherited ataxias, 419-424  
 "Domino effect", HIV-infected cells in the brain leading to progressive loss of neuronal function, 122  
 Duchenne muscular dystrophy, 5-7, 10-15, 87-88, 323-330  
 Dystonia, the most simple classification subdivides into primary or secondary, 271-272  
 Dystrophin, 10, 12, 14-16  
 Dystrophin-glycoprotein complex, core components of, 10  
 Dystrophinopathies, clinical features, laboratory features, genetics, molecular pathogenesis of the, treatment, 11-15
- EBV, *see* Epstein-Barr virus  
 EBV as a console factor for PCNSL in association with AIDS, 215  
 EDMD, *see* Emery-Dreifuss muscular dystrophy  
 Electrophysiology, nerve conduction studies in EDMD, 71  
 Emery-Dreifuss muscular dystrophy, history of, clinical features, cardiac manifestations of, diagnosis of, treatment of, 67-70, 75-76  
 Endogenous toxins, 121-122  
 Epidemic, epidemiology of the AIDS virus, 130-131  
 Epidemiology, of neurologic diseases associated with HIV infection, 109  
 Episodic disorders affecting excitable tissues, 364  
 Epstein-Barr virus, 189, 215, 225  
 Expanded repeat sequences and disease, 289-296  
 Expanded repeats, methods for detection and isolation of, 295-296  
 Expanded sequences, repeats and mechanisms of, 290-291
- Facioscapulohumeral dystrophy, historical note, clinical features, laboratory features, molecular genetics of, diagnosis of, treatment of, 5-6, 35-42  
 Familial Alzheimer disease, 378-379  
 Filamentous intranuclear inclusions, identification of a morphological marker for OPMD  
 Fragile X mental retardation, the most common form of inherited mental retardation is, 294  
 Frataxin gene, point mutations in the, 316  
 Frataxin, the function and pathogenesis of, 316-317  
 Free radicals, Friedreich's ataxia and the role of, 317  
 Friedreich's ataxia, clinical aspects and pathogenesis of, 311-318  
 Friedreich's ataxia, epidemiology of, 312  
 Friedreich's ataxia, the identification as a triplet repeat disorder, 294  
 Function disorders in relation to expanded repeats, 293-294
- Gene amplification, 223  
 Gene mutations causing several neurologic disorders, 304  
 Gene therapy of DMD, requirements for the, 325-326  
 Gene therapy, Duchenne muscular dystrophy and the progress toward, 323-330  
 Gene therapy, myoblast transfers for the muscular dystrophies  
 Generalized epilepsy with febrile seizures plus, 400-401  
 Genetic analysis of HSP, 302-303  
 Genetic analysis of MS, case-control versus family-based study designs, 283-284  
 Genetic aspects of multiple sclerosis, 281-287  
 Genetic disorders of motor neurons, 407-415  
 Genetic risks, DNA testing has important genetic counseling implications, 255  
 Genetic susceptibility, its role in the etiology of most MS cases, 281-282  
 Genetic testing of OXPHOS diseases, 345  
 Genetics of epilepsy, relevance of findings to clinical practice, 403
- Genetics of primary dystonia, 271-278  
 Genome searches underscore a role for the MHC, 286-287  
 Genomic screen, 286-287  
 Gowers, textbook revisited, early observations on muscular dystrophy, 87-92  
 Growth factors, growth hormone and insulin-like, 83-84  
 Gutted adenoviral vectors, 328-329
- HD, *see* Huntington disease  
 HD patients, recent insights from a human database of, 386-388  
 Heart disease, in patients with Friedreich's ataxia premature death may be contributed to by, 313  
 Heart, Friedreich's ataxia and the typical pathology of the, 312-313  
 Hepatic presentation, recognizing Wilson's disease in patients with, 262-263  
 Hereditary sensory neuropathies, 357-358  
 Hereditary spastic paraplegia, 301-307, 410  
 Herpes simplex virus, another important virus to be considered in the setting of HIV is, 188-189  
 History of neurology, 235-237  
 HIV, *see* human immunodeficiency virus  
 HIV dementia, viral load and, 115  
 HIV infection, surveillance of, AIDS as a proxy indicator of, 107  
 HIV-associated dementia, clinical and pathologic features of, 131-146  
 HSP, *see* hereditary spastic paraplegia  
 Human herpesvirus-6, 189-190  
 Human immunodeficiency virus infection, history and prospects, transmission and risk factors of, 105-106  
 Human immunodeficiency virus type-1, 165-174  
 Human immunodeficiency virus, 105-110, 113-122, 129-146, 151-154, 157-163, 165, 185-190, 202-203, 223-229  
 Human infection with *T. gondii*, 202  
 Huntington disease, clinical and neuropathological features of, 386
- Idiopathic epilepsies with known gene defects, 398-402  
 Idiopathic epilepsies with known genetic loci, 402-403  
 IGF-1, double-blind, placebo-controlled trial in myotonic dystrophy, 84  
 Imaging characteristics, the diagnosis of PCNSL may be suggested by findings on, 216  
 In vitro models of HD, recent insights from, 392-394  
 Infected cells, in relation to HIV, 115-116  
 Infectious myelopathies, cause of spinal cord disease in HIV infection, 153-154  
 Inflammatory demyelinating polyneuropathy, a relatively infrequent HIV-associated peripheral neuropathy is, 161  
 Inheritance model for multiple sclerosis, 287  
 Inherited peripheral neuropathy, 353-359  
 Insurance, the sharing of DNA test results is especially pertinent in the context of, 257  
 Ion channel diseases in humans, the periodic paralyses definition, 365-367  
 Ion channel diseases, 363-367  
 Ischemic myelopathy, noninfectious cause of disease in AIDS, 154
- JC virus, the PML disease results from infection with the, 194-195
- Kayser-Fleischer rings, an excellent diagnostic tool in neurological presentations are, 263

- Kearns-Sayre and chronic progressive external ophthalmoplegia syndromes, 345-346  
 Kennedy's disease, 291, 410-411  
 Kinetics of virologic suppression, 143
- Lactic acidosis, 346  
 Laing distal myopathy, 50-51  
 Learning disorders, HIV-1-associated CNS disease can frequently lead to, 169  
 Leber's hereditary optic neuropathy, 347  
 Legal counseling, DNA testing and, 258  
 Leigh disease, 348  
 Limb-girdle muscular dystrophy, original definition of, clinical features, laboratory features, genetics, molecular pathogenesis of the, treatment, 15-17  
 Liver biopsy, the gold standard of Wilson's disease diagnosis is, 264  
 Liver disease, the prognosis of Wilson's disease, 268  
 Lymphoma of the central nervous system in AIDS, 213-219
- Major histocompatibility complex, the genetic association between MS susceptibility and the, 284-286  
 Markesbery-Udd distal myopathy, clinical features, laboratory features, molecular genetics of, 46-47  
*Mdx* mice, prevention of dystrophy in, 326  
 Meiotic unequal crossover, genesis of CMT1A and HNPP, 356-357  
 Membrane instability, unifying hypothesis of, 11  
 Meningitis, 178-179  
 Metabolic testing in OXPHOS diseases, 344  
 Methods of cerebrospinal fluid analysis, 224  
 MHC, *see* major histocompatibility complex  
 Microglial cells, 115  
 Migraine headache and epilepsy, the most common episodic phenomena encountered by neurologists are, 364  
 Mitochondrial DNA mutations, 345  
 Mitochondrial encephalomyopathy, 346  
 Miyoshi distal myopathy, clinical features, laboratory features, molecular genetics of, 49-50  
 Molecular genetics of Alzheimer disease, 371-379  
 Molecular genetics of Friedreich's ataxia, 315-316  
 Molecular pathogenesis of Huntington disease, 385-394  
 Molecular testing, Friedreich's ataxia and the role of, 314-315  
 Monotherapy, effects of the treatment on HIV dementia, 144-145  
 Motor neuron degeneration and dementia, 414-415  
 MS, *see* multiple sclerosis  
 Multiple sclerosis, gene identification in, 282-283  
 Muscle biopsy, in EDMD, 71-73  
 Muscle tissue, delivery of adenoviral vectors to, 329-330  
 Muscular dystrophy, 5-7, 9-20, 35-42, 45-55, 59-64, 81-85  
 Mycobacterial infections, 177-179  
 Mycobacterial meningitis, 179  
*Mycobacterium tuberculosis*, 178-179  
 Myoclonic epilepsy and ragged-red fiber disease, 346  
 Myofibrillar myopathy, clinical features, laboratory features, molecular genetics of, 51-52  
 Myopathies with distal weakness, childhood-onset, muscular dystrophies, inflammatory myopathies, metabolic and congenital myopathies, neuromuscular junction disorders, 53-55  
 Myopathy, associated with HIV, 162-163  
 Myotonia, 27-28, 31  
 Myotonic dystrophies, genetics of, pathophysiology, clinical features, treatment of, 25-28, 30-31  
 Myotonic dystrophy caused by a CTG expansion, 293-294  
 Myotonic dystrophy, 5-7, 25-31  
 Myotonic myopathy, 25, 30-31
- Negative DNA tests, two cautions must be noted with, 255  
 Nervous system, involvement in HIV infection, 108-109  
 Neurobehavioral aberrations, increasing evidence in HIV-1 infected children, 168-169  
 Neurocognitive deficits in different stages of HIV infection, 133  
 Neuroimaging, radiographic imaging may strongly support the diagnosis of PML, 197  
 Neurologic disease, studies of viral load in HIV, 142  
 Neurologic diseases related to HIV and AIDS, 109  
 Neurologic disturbances due to toxoplasmosis, 205  
 Neurologic manifestations of toxoplasmosis in AIDS, 201-209  
 Neurological manifestations of Wilson's disease, symptomatic treatment of, 267-268  
 Neurological presentation, recognizing Wilson's disease in patients with, 263  
 Neurological signs and symptoms associated with Friedreich's ataxia, 313  
 Neurology trivia, 235-237  
 Neuronal cell loss, 116  
 Neuropathology and pathogenesis of *T. gondii*, 202  
 Neurophysiological investigations into Friedreich's ataxia, 314  
 Neuroradiologic examinations in HIV-1 infection, 171  
 Neurosyphilis, 180-181  
 Neurotoxicity, tumor necrosis factor-mediated events that contribute to, 121  
 Nitric oxide, HIV infection and neurotoxic events, 122  
 Nonaka distal myopathy, clinical features, laboratory features, relationship to familial inclusion body myopathy, molecular genetics of, 47-49  
 Nutritional deficiencies, children with HIV-1 infection are prone to, 170-171
- Oculopharyngeal muscular dystrophy (OPMD), historical background, early descriptions of, clinical definition of, 59-60  
 Onset of Friedreich's ataxia, 313  
 OPMD, *see* Oculopharyngeal muscular dystrophy  
 Opportunistic infections in relation to HIV-1 infection in older children, 169  
 Opportunistic infections, in relation to HIV-related neurological diseases, 224-229  
 Oxidative phosphorylation disease diagnosis, 341-349  
 OXPHOS, *see* oxidative disease diagnosis  
 OXPHOS disease, nuclear DNA mutations and, 347-348
- PABP2* gene, 59, 62-64  
 Parkinsonism, dystonia associated with, 277  
 Paroxysmal dystonia, 275-276  
 Pathologic examination of PCNSL, 214  
 Pathology and prognosis of PML, 197-198  
 PCNSL, *see* primary CNS lymphomas  
 Pelizaeus-Merzbacher disease, proteolipoprotein gene mutations cause, 303-304  
 Penicillamine, the first orally effective drug developed for Wilson's disease was, 265-266  
 Peripheral neuropathy, most frequent neurologic complication of HIV infection, 158-162  
 Pharmacologic therapy, intervention in the muscular dystrophies, 82  
 Phenotype-genotype correlations, gene mutations and, 421  
 Phenotypes, OXPHOS diseases present with a broad array of, 344

- Plasma HIV levels, 142
- PML, *see* progressive multifocal leukoencephalopathy
- Polyadenylation binding protein 2 (*PABP2*) gene, OPMD is caused by short GCG expansions in the, 60–63
- Polyalanine nuclear toxicity, a molecular pathophysiologic hypothesis for OPMD, 63–64
- Polyglutamine disorders, the most commonly found pathogenic repeat is CAG, 291–293
- Position effect variegation hypothesis, 41
- Positional cloning, an alternative strategy to the analysis of individual candidate genes is, 286
- Prednisone, 81–83
- Prenatal DNA testing, complex issues surrounding, 258
- Presenilin 1, 374–376
- Presenilin 2, 377–378
- Pressure palsies, hereditary neuropathy with liability to, 355
- Prevention of HIV infection, 174
- Prevention, three levels associated with HIV infection, 109–110
- Primary CNS lymphomas, 214–218
- Primary dystonia, 274–275
- Primary torsion dystonia, early-onset generalized PTD, dystonia I, 274
- Prognosis and treatment for PCNSL, 217
- Progressive encephalopathy, associated with neurologic disease in children, 166–168
- Progressive multifocal leukoencephalopathy, an overview, 193–194
- Progressive myoclonus epilepsy of the Unverricht–Lundborg type, 401–402
- Progressive polyradiculopathy, common in HIV-infected patients with advanced immunosuppression, 161–162
- PROMM, *see* proximal myotonic myopathy
- Prophylaxis, prevention of toxoplasmic encephalitis recurring having been suppressed, 208–209
- Proteolipoprotein, a gene that has been discovered for types of complicated HSP is, 304
- Proximal myotonic myopathy, 25, 31
- Psychiatric presentation, recognizing Wilson's disease in patients with, 263
- Psychiatric symptoms as a reaction to chronic illness, 168–169
- PTD, *see* primary torsion dystonia
- Quinolinic acid, levels associated in patients with HIV encephalopathy, 121–122
- Radiation therapy in PCNSL, 217–218
- Rare monogenic episodic disorders, genetic and biological study of, 364–365
- Risks and benefits of DNA testing for neurogenetic disorders, 253–259
- Second generation adenoviral vectors, 328
- Skeletal muscle pathology in OXPHOS diseases, 344–345
- Spinal cord, diseases associated with HIV infection, 151–154
- Spinal muscular atrophy, pathology and diagnosis of, genetics of, mechanism of the disease, 407–408
- Spinocerebellar ataxia, 291
- $\beta$ -adrenergic agents, 84
- Steroid therapy, 82–83
- Stress and anxiety related to predictive DNA testing, 256
- Susceptibility genes in human epilepsy, 397–403
- Systemic aids-related lymphoma with CNS involvement, 219
- Terminology describing HIV dementia, 132
- Testing for Wilson's disease, 263–264
- Therapeutic trials of muscular dystrophy, then . . . and now, 81–82
- Therapy in the muscular dystrophies, overview, 81
- Therapy of toxoplasmosis in AIDS, 207–208
- Tissue biopsy in the diagnosis of PCNSL, 216
- Toxoplasma gondii*, life cycle of, 201–203, 205–209
- Toxoplasmic encephalitis, 203, 206–207
- Toxoplasmosis, 201, 205–206
- Transgenic mouse model of HD, recent insights from a, 388–391
- Treatment of children with HIV-1 infection, 172–174
- Trientine, an FDA-approved substitute in patients intolerant of penicillamine is, 266
- Trinucleotide, in relation to expanded repeat sequences, 289
- Tuberculoma, 178–179
- Tumor necrosis factor, implications in the pathogenesis of HIV infection, 121
- Urine copper test, diagnosis of Wilson's disease using the, 263
- Vacuolar myelopathy, most common spinal cord disease in HIV-infected individuals, 151–153
- Varicella zoster virus, neurologic manifestations of, 188
- Viral latency, seroepidemiologic studies and, 195
- Virotoxins, mechanisms of release into extracellular environment, transport of, 117–118
- Welander distal myopathy, clinical features, laboratory features, molecular genetics of, 46
- Wilson disease, 348
- Wilson's disease, recognition of, diagnosis of, 262–263
- Wolfram syndrome, 348
- X-linked Charcot–Marie–Tooth neuropathy, 357
- X-linked HSP, 303, 305–306
- Zinc, the most recently FDA-approved drug for the treatment of Wilson's disease is, 265



